LRRK2 Is Recruited to Phagosomes and Co-recruits RAB8 and RAB10 in Human Pluripotent Stem Cell-Derived Macrophages
Year: 2020
Type: article
Abstract: The Parkinson's disease-associated gene, LRRK2 , is also associated with immune disorders and infectious disease and is expressed in immune subsets. Here, we characterize a platform for interrogating the expression and function of endogenous LRRK2 in authentic human phagocytes using human induced pluripotent stem cell-derived macrophages and microglia. Endogenous LRRK2 is expressed and upregulated by interferon-γ in these cells, including a 187-kDa cleavage product. Using LRRK2 knockout and G2019S isogenic repair lines, we find that LRRK2 is not involved in initial phagocytic uptake of bioparticles but is recruited to LAMP1 + /RAB9 + "maturing" phagosomes, and LRRK2 kinase inhibition enhances its residency at the phagosome. Importantly, LRRK2 is required for RAB8a and RAB10 recruitment to phagosomes, implying that LRRK2 operates at the intersection between phagosome maturation and recycling pathways in these professional phagocytes.
Source: Stem Cell Reports
Authors: Heyne Lee(Conceptualization, Formal analysis, Investigation, Methodology, Writing – original draft, Writing – review & editing), Rowan Flynn(Investigation, Methodology, Resources), Ishta Sharma(Formal analysis, Investigation), Emma Haberman(Formal analysis, Investigation), Phillippa J. Carling(Methodology), Francesca J. Nicholls(Methodology), Monika Stegmann(Methodology, Resources), Jane Vowles(Resources), Walther Haenseler(Methodology), Richard Wade-Martins(Funding acquisition, Resources, Supervision), William S. James(Conceptualization, Funding acquisition, Resources, Supervision, Writing – review & editing), Sally A. Cowley(Conceptualization, Formal analysis, Funding acquisition, Investigation, Methodology, Resources, Supervision, Writing – original draft, Writing – review & editing)
Institutions: University of Oxford, Warneford Hospital
Language: English
Subfield: Cell Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,800
Funders: Wellcome Trust, European Federation of Pharmaceutical Industries and Associations, Alzheimer's Research Trust, Stem Cell Network, National Institute for Health and Care Research, Parkinson's UK, University of Oxford, European Commission, Innovative Medicines Initiative, Dementias Platform UK, Otsuka Pharmaceutical Development and Commercialization, Medical Research Council, Oxford Martin School, University of Oxford, Seventh Framework Programme
Awards: JPND Alpha-synuclein pathology propagation in Parkinson's disease and quest for novel protective strategies, G1010233069, UK Dementias Platform, UK Dementias Platform, G1397628908, Dementias Platform UK Stem Cell Partnership, G1595590610, G1681111766, University of Oxford Momentum Award – Dementias, G2050123317, G208506829, G2247181945, G3016911957, G3527764968, G3797955763, G3853438144, UKDP: Integrated DEmentiA research environment (IDEA), G429673011, G4544071696, G4653495942, G5181896033, Stem cells for Biological Assays of Novel drugs and prediCtive toxiCology (StemBANCC), G5300737479, Protection of neurons in vitro and in vivo from Synuclein toxicity by molecular tweezers, G5558911907, G588473525, G6073002028, G6292285981, G677748830, Understanding the genetic basis of common human diseases: core funding for the Wellcome Trust Centre for Human Genetics., UKDP: Integrated DEmentiA research environment (IDEA), G738203952, G819757714, G8501662357, G8621185791, G8975541179
OpenAlex ID: W3014129098
